secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sionna Therapeutics, Inc. (SION)
CIK:        0002036042
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001193125-25-058306
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sionna Therapeutics FY2024 net loss $61.7M; cash $168M plus $199.6M IPO net proceeds extend runway into 2028
--------------------------------------------------------------------------------

- Net loss Q4 2024 $15.8M, full year $61.7M vs $47.3M in 2023; R&D spend $57.3M.
- Cash, equivalents and marketable securities $168.0M as of Dec 2024; excluding $199.6M net IPO proceeds from February 2025.
- Upsized IPO raised $219M gross ($199.6M net) in Feb 2025; shares trading on Nasdaq under SION.
- Phase 1 MAD dosing completed for SION-451; final MAD cohort for SION-719 planned; topline data expected H1 2025.
- Plan to initiate Phase 2a POC trial in CF patients H2 2025 with topline data mid-2026; combination MAD trials also planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2036042/000119312525058306/0001193125-25-058306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2036042/000119312525058306/d679677d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-058306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer